4.9  0.85 (20.99%)		05-18 16:00
Open: 4.16 High: 5 Volume: 114,537		Pre. Close: 4.05 Low: 4.095 Market Cap: 146(M)

Short term
Mid term
Targets	6-month :	5.84	1-year :	6.82
Resists	First :	5	Second :	5.84
Pivot price	3.88
Supports	First :	3.85	Second :	3.14
MAs	MA(5) :	4.19	MA(20) :	3.78
	MA(100) :	3.76	MA(250) :	0
MACD	MACD :	0.2	Signal :	0.1
%K %D	K(14,3) :	92	D(3) :	91.7
RSI	RSI(14): 84.9
52-week	High :	26.5	Low :	2.56

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ TTRX ] has closed Bollinger Bands are 21.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5 - 5.02	5.02 - 5.03
Low:	4.06 - 4.07	4.07 - 4.09
Close:	4.87 - 4.9	4.9 - 4.93

Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.

Tue, 19 May 2026
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 - Business Wire

Mon, 18 May 2026
Turn Therapeutics Appoints Former FDA Chief to Lead GX-03 - TipRanks

Mon, 18 May 2026
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead - Business Wire

Sat, 25 Apr 2026
Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher - Should You Buy? - MarketBeat

Tue, 24 Mar 2026
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - BioSpace

Thu, 08 Jan 2026
Turn Therapeutics Reaches US$132m Market Cap Benefiting Insider Stock Buying - simplywall.st

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	30 (M)
Shares Float	11 (M)
Held by Insiders	63.7 (%)
Held by Institutions	1.7 (%)
Shares Short	60 (K)
Shares Short P.Month	63 (K)

EPS	-0.13
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.01
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	-129.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.04
Sales Per Share	0
EBITDA (p.s.)	-0.26
Qtrly Earnings Growth	0 %
Operating Cash Flow	-4 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-37.7
PEG Ratio	0
Price to Book value	245
Price to Sales	0
Price to Cash Flow	-37.43

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.